secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2026-03-26T23:59:59+00:00
Accession:  0001493152-26-012915
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iMDx submits GraftAssureDx to FDA; Q4 revenue $1.1M, net loss $23.0M
--------------------------------------------------------------------

- Submitted GraftAssureDx kidney transplant test to FDA on March 25; expects 150-day review and authorization this year.
- Full year 2025 revenue $4.1M (up from $1.9M); Q4 revenue $1.1M, net loss $23.0M ($0.72/share).
- Adjusted Q4 net loss $8.7M ($0.27/share); R&D expenses rose 50% sequentially to $5.8M due to FDA submission.
- Impaired oncology intangibles $14.6M ($11.7M DetermaCNI, $2.9M DetermaIO) to focus on transplant.
- Appointed Dr. Nick Ioannou as VP Medical Affairs; completed $26M financing in February for heart expansion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315226012915/0001493152-26-012915-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315226012915/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-012915

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer